The Brazilian perspective on the TRIPS Waiver Expansion for COVID-19 Drugs and Testing: Lessons learned from past experiences, current data on reality and possible suggestions for solving the problem.

Fernandes Maciel, Vladimir; Gallo Antonio, Allan Augusto

doi:10.5281/zenodo.8387262

Published May 5, 2023 | Version v1

Report Open

The Brazilian perspective on the TRIPS Waiver Expansion for COVID-19 Drugs and Testing: Lessons learned from past experiences, current data on reality and possible suggestions for solving the problem.

1. Mackenzie Center for Economic Freedom

Technical Report on the Expansion of TRIPS Waiver for COVID-19 Medicines and Tests. Report Submitted to the United States International Trade Commission.

Files

Technical Report_TRIPS_2023.pdf

Files (297.2 kB)

Name	Size	Download all
Technical Report_TRIPS_2023.pdf md5:f47f51eff4f9f722e4fcfee6036ecfd4	297.2 kB	Preview Download

Views

Downloads

Show more details

	All versions	This version
Views	46	45
Downloads	42	41
Data volume	12.8 MB	12.5 MB

More info on how stats are collected....

DOI

Resource type

Report

Publisher

Zenodo

Languages

English

Creative Commons Attribution 4.0 International

The Creative Commons Attribution license allows re-distribution and re-use of a licensed work on the condition that the creator is appropriately credited. Read more

Technical metadata

Created: September 28, 2023
Modified: July 11, 2024

The Brazilian perspective on the TRIPS Waiver Expansion for COVID-19 Drugs and Testing: Lessons learned from past experiences, current data on reality and possible suggestions for solving the problem.

Creators

Description

Files

Technical Report_TRIPS_2023.pdf

Files (297.2 kB)